Daratumumab and TAK-079 lack the ability to directly induce MM cell death [11]; however, FcγR-mediated cross-linking of daratumumab induces programmed cell death of CD38-positive MM tumor cell lines [10]. This evidence concerns the gene FCGR2A and Miyoshi myopathy.